Pre-referral rectal artesunate in severe malaria

The Lancet

Volumn 373, Issue 9663, 2009, Pages 522-523

  von Seidlein, Lorenz ^a   Deen, Jacqueline L ^a,b  

^a Joint Malaria Programme   (Tanzania)

^b International Vaccine Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE;

ARTICLE; BANGLADESH; CLINICAL RESEARCH; DISEASE SEVERITY; DRUG SAFETY; GHANA; HOSPITALIZATION; HUMAN; INFECTION RATE; PATIENT REFERRAL; PLASMODIUM MALARIAE INFECTION; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; TANZANIA; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 59949098021     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61735-3     Document Type: Note

References (5)

1. Gomes M.F., Faiz M.A., Gyapong J.O., et al., for the Study 13 Research Group. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet (2008) 10.1016/S0140-6736(08)61734-1 published online Dec 8.
2. International Artemisinin Study Group. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363 (2004) 9-17
3. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366 (2005) 717-725
4. Karunajeewa H.A., Manning L., Mueller I., Ilett K.F., and Davis T.M. Rectal administration of artemisinin derivatives for the treatment of malaria. JAMA 297 (2007) 2381-2390
5. Gomes M., Ribeiro I., Warsame M., Karunajeewa H., and Petzold M. Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies. BMC Infect Dis 8 (2008) 39